Bayer and the Income Dream: 40,000 Shares to Live Off Dividends

Bayer and the Income Dream: 40,000 Shares to Live Off Dividends

Buying 40,000 Bayer shares and waiting for the price to reach €80 is, mathematically speaking, the cleanest recipe to stop working. Forty thousand shares bought in the vicinity of twenty euros and sold at 80 represent a capital gain of 2.4 million euros. If the dividend also returns to 2.4 euros per share, the final account balances a net worth of 3.2 million and an annual income of gross €100,000, taxed at an estimated rate of 20%. On paper, it is flawless.

The reality has more angles. The first hurdle dismantles the exercise: who has nearly one million euros in liquidity to put on the table. Without that starting capital, the plan doesn't exist, no matter how correct the thesis may be.

From €18 to €46: What has peine with Bayer

The thesis was launched when the stock was trading in the vicinity of twenty euros. Since then, and according to the very figures used by those who trinc the stock's value, the price doubled: from a minimum of €18 to €36 in just one year. Some entered at 27 in October and sold later in two installments, near 45 and 38, with profits secured. In recent phases, the €46 mark has been exceeded, and the chart points toward 50.

The central argument is not new. A company trading far below its value, a CEO presented as an expert in corporate management, a marked floor price, and a buying dynamic that becomes explosive once the resistance of those caught in the dip is broken. The technical reading holds that below €30, shareholders were accumulating shares, assuming their error, and that the rise with volume cleared this selling pressure. Those who sold earlier now face another resistance: that of those still holding inside.

The Never-Ending Litigation and Judge Boyer

No serious valuation analysis holds up without the lawyer present. The Monsanto inheritance and glyphosate continue to dictate the price, and figures used in the toughest scenarios speak of potential losses amounting to 30 billion dollars, with bankruptcy of the subsidiary as an extreme hypothesis. The method repeated is always the same: calculate the worst-case scenario, compare it with the company's free cash flow, assets, and net profit, and check if the stock drop already discounts that disaster. If the answer is yes, there is room.

The legal process advances at its own pace. The revocations of opt-outs continue to be processed, even until the final approval, and the definitive number will not be known until Judge Boyer makes his decision. The surname of the magistrate, Boyer, versus Bayer, has provided entertainment for the most ironic, who are already calling for a prosecutor with the surname MontSainte to close the joke.

The Dividend: The Double Tax Trap in Germany

In the medium term, what attracts investors is not the capital gain, but the income. The idea of securing a lifetime pension from a large company over 40 or 45 years, without depending on a salary, has an attraction that is difficult to exaggerate. The problem arises with the Tax Authorities. Germany levies tax on non-residents, and double taxation requires chasing papers and bureaucracy to recover part of it. In the Spanish case, 15% is withheld, and then one must account for the own bracket, with a minimum extra amount, leaving the effective rate above 30% in most scenarios. Those seeking clean European income usually look to the Netherlands or the United Kingdom.

The Two Sides of the Investor Coin: Buy In or Watch

The division is not whether Bayer is cheap, but whether the deal is already done. One side maintains that the big payoff has occurred and that staying invested now is riskier than entering at 20. The other defends that the company is worth what it was a year ago, that debt has decreased, and that the stock price is merely approaching its normal multiples. Some also warn that if the German pharmaceutical company stumbles with US tariffs, the whole story collapses.

An interesting and not insignificant detail: the portfolio cited as a reference is not a single stock. The list ranges from Atresmedia, bought at 2.2 euros and already distributed 2.4 in dividends, to Currys, Porsche, Hellofresh, Victoria, or a regional US banking firm. The underlying thesis is not specifically Bayer, but a handful of companies trading far below what is considered a reasonable price, several of which are in potential takeover bid situations. The complete calculation, item by item, is what gives the investment its real weight.

Spin-offs as the Next Playcard

The hypothesis discussed for the next phase is a possible segregation of divisions to relaunch the value: a spin-off or partial sale of units to another fund or company. If this occurs, the market could reprice the whole entity and justify a rise beyond a simple return to the miccionan. The results from late January, according to those trinc the value, were adequate and arrived at the perfect time to sustain the momentum.

What Remains Unresolved

The tariff uncertainty, the judge's calendar, and the evolution of the technology bubble are three open fronts that could drag Bayer down even if the company fulfills its part. The current dynamic is one of a value that rises when there are good pieces of news and also when there is no news. That is tendency, not valuation. With Bayer above €46, the question is no longer whether entering at 20 was worth it, but how much of the pending rise has already been discounted by the market. We will probably know that when Boyer signs off.